United States · Exchanges & live quotes · Nasdaq
Johnson & Johnson Set To Buy Ollin Biosciences For Up To $3.4 Bln: Report
Detailed summary
(RTTNews) - Johnson & Johnson (JNJ) is close to acquiring eye disease drug developer Ollin Biosciences in a deal valued at up to $3.4 billion, according to a Financial Times…
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.nasdaq.com)

